Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy.

摘要: ABSTRACTIntroduction: Autoimmune hepatitis (AIH) is an immune-mediated liver disease, which requires long-term immunosuppression. Ten to fifteen percent of patients experience insufficient/intolerance response standard therapy. Although alternate immunosuppression has been applied, there little data reported on safety, efficacy, steroid-dose reduction and disease evolution in with difficult AIH who were Tacrolimus Materials methods: Clinical, biochemical, immunological profiles, treatment side effects 17 treated between 2003 2014 analyzed from two tertiary referral centers. Results: was started 16/17 (94%) due insufficient The median duration 24 months followed up for 60 months. dosage 2 mg/day (median). During first year therapy, a significant improvement immunoglobulin G and...